Skip to NavigationSkip to content

job cuts

AstraZeneca to shut down twin Colorado manufacturing sites, impacting over 200 jobs

UK-based drug firm AstraZeneca has revealed it is set to shed more than 200 positions from its operations at two sites in the US state of Colorado in a bit to consolidate and bolster operational efficiency.

The cutbacks, made in the counties of Boulder and Longmont, are in the name of amalgamating “the biologics manufacturing network in one large-scale drug substance facility”, according to the company.

Boehringer's France restructure will cull over 300 jobs

Boehringer Ingelheim is set to follow in the recent steps of Sanofi with the announcement of a cull of over 300 employees in France – around 10% of the company’s total workforce in the country.

The German drug company confirmed the plans to unions, explaining that the move is designed to reorganise operations in and around its hub in the French city of Lyon.

Bayer announces major restructure, 12,000 jobs to go

Bayer has announced a major restructure of its operations in 2019 which will see the loss of 12,000 of its 118,200 positions following a number of lawsuits in the wake of its $63 billion buyout of agricultural biotech firm Monsanto.

The move “aims to strengthen its core life science businesses through a series of portfolio, efficiency and structural measures designed to enhance productivity and innovation while significantly improving competitiveness,” the company said.

The company’s Supervisory Board was said to have unanimously expressed support for the move.

GSK to cut almost 200 jobs at UK site

GlaxoSmithKline has announced that it is to slash half of its workforce at its site in Ulverston, UK, as part of a move to cull cost-ineffective operations.

The company said that 191 of its staff could be faced with redundancy of a total of 347. The first wave of losses will be felt in June 2019, with the rest to follow in 2020.

The cuts hit the sterile injectables part of the business, which will close as it has been deemed as not cost-effective, but the company confirmed its tablet manufacturing department would continue to see investment.

MSD cuts 1,800 jobs in US operations restructure

MSD has revealed its intention to cut 1,800 sales positions from its workforce in the US. Across the total number, the cuts include the elimination of US sales teams in primary care, endocrinology and hospital chronic care. In their place, the company will add 960 positions with the formation of a new chronic care sales force.

This new force will focus on key products in the company’s pipeline including its diabetes treatment Januvia (sitagliptin) and insomnia therapy Belsomra (suvorexant) in addition to women’s health and respiratory disease products.

AZ to terminate 700 US jobs

AstraZeneca has revealed that it plans to cut 700 positions across the US by 10 February 2017, including 120 positions at its US headquarters in Wilmington, Delaware, as part of the company’s growth strategy.

"These changes reflect the ongoing focus to further streamline and drive greater efficiency across the entire organization," the firm said in a statement. "We continue to face loss of exclusivity impacts from many of our legacy products and work to compete in an ever-changing external environment."

Novo Nordisk to cut 2% of its entire workforce

Novo Nordisk, headquartered in Bagsvaerd, Denmark, has taken the decision to lose 1,000 of its workforce from a total global workforce of 42,300. Novo released a statement suggesting that the cuts will predominately take place in R&D and headquarter staff functions, as well as wider positions within the global commercial organisation.

MSD to cut 148 jobs at Pennsylvania plant

MSD is due to cut 148 jobs at its North Wales, Pennsylvania campus effective September 12, according to the company’s Worker Adjustment and Retraining Notification filed with the State Department.

Spokeswoman Lainie Keller remarked that the decision is a result of the company’s move to cease production of its heart drug Zontivity after September 2, meaning that field-based team members and other HQ-based roles will be displaced.  

Roche confirms over 200 job cuts at Irish facility

Swiss pharmaceutical company Roche (VTX: ROG) has confirmed that 240 jobs are to go at their Irish site in Clare, which is set to close by 2019.

The company had originally announced its intention to leave the site late last year, but indicated that it would attempt to transfer the plant to a global pharma services company. These negotiations, however, were unsuccessful.

The facility in Clarecastle has been operational since 1974, and is Roche’s only operational presence in Ireland.

Clovis cuts staff by 35% after FDA knock back on lung cancer drug

Clovis Oncology (NASDAQ: CLVS) is set to cut up to 35% of its workforce following the US Food and Drug Administration’s decision not to recommend rociletinib for priority review.

The move was announced along with their first quarter results, which also saw the company make a massive net loss with expenses on research and development rising over 30% from the previous year.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches